Novel rational drug design strategies with potential to revolutionize malaria chemotherapy

Current Medicinal Chemistry

Volumn 18, Issue 1, 2011, Pages 113-143

  Muregi, F W ^a,b   Kirira, P G ^c   Ishih, A ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c KYOTO UNIVERSITY   (Japan)

Author keywords

Antimalarial drugs; Apoptosis; Hybrid drugs; Plasmodium falciparum; Prodrugs; Topoisomerases

Indexed keywords

4 AMINOQUINOLINE; ACYL CARRIER PROTEIN; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; CAMPTOTHECIN; CASPASE; CASPASE 3; CHLOROQUINE; CLINDAMYCIN; CYCLIN DEPENDENT KINASE; CYSTEINE; DIAMIDINE DERIVATIVE; DIHYDROARTEMISININ; DIHYDROOROTATE DEHYDROGENASE; DNA; FALCIPAIN 2; FATTY ACID SYNTHASE; FERROCHELATASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MEFLOQUINE; PEPTIDOMIMETIC AGENT; POTASSIUM ION; PYRAMAX; PYRIMIDINE; REACTIVE OXYGEN METABOLITE; RNA POLYMERASE; SODIUM ION; TUMOR NECROSIS FACTOR ALPHA; UBIQUINONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROPORPHYRINOGEN;

AMINO TERMINAL SEQUENCE; APICOMPLEXA; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CELL PROLIFERATION; CHEMOTHERAPY; DNA FRAGMENTATION; DRUG DESIGN; DRUG RESISTANCE; HISTONE ACETYLATION; MALARIA; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; APOPTOSIS; DNA TOPOISOMERASES; DRUG DESIGN; HUMANS; MALARIA; PRODRUGS; TOPOISOMERASE INHIBITORS;

EID: 78751550062     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711793979742     Document Type: Article

References (383)

1. WHO, 2010. Fact Sheet No. 94 on Malaria. http://www.who.int/mediacentre/ factsheets/fs094/en/(Accessed June, 2010).
2. Schlitzer, M. Malaria chemotherapeutics part I: History of antimalarial drug development, currently used therapeutics, and drugs in clinical development. Chem. Med. Chem., 2007, 2, 944-986.
3. White, N. J. Plasmodium knowlesi: the fifth human malaria parasite. Clin. Infect. Dis., 2008, 46, 172-173.
4. Van den Eede, P.; Van, H. N.; Van Overmeir, C.; Vythilingam, I.; Duc, T. N.; Hungle, X.; Manh, H. N.; Anne, J.; D'Alessandro, U.; Erhart, A. Human Plasmodium knowlesi infections in young children in central Vietnam. Malar. J., 2009, 8, 249.
5. Sponer, U.; Prajakwong, S.; Wiedermann, G.; Kollaritsch, H.; Wernsdorfer, G.; Wernsdorfer, W. H. Pharmacodynamic interaction of doxycycline and artemisinin in Plasmodium falciparum. Antimicrob. Agents Chemother., 2002, 46, 262-264.
6. WHO, 2009. World Malaria Report 2009. http://www.who.int/malaria/ publications/atoz/9789241563901/en/i ndex.html (Accessed June, 2010).
7. Gregson, A.; Plowe, C. V. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev., 2005, 57, 117-145.
8. Rosenthal, P. J. Proteases of malaria parasites: new targets for chemotherapy. Emerg. Infect. Dis., 1998, 4, 49-57.
9. Amewu, R.; Stachulski, A. V.; Ward, S. A.; Berry, N. G.; Bray, P. G.; Davies, J.; Labat, G.; Vivas, L.; O'Neill, P. M. Design and synthesis of orally active dispiro 1, 2, 4, 5-tetraoxanes; synthetic antimalarials with superior activity to artemisinin. Org. Biomol. Chem., 2006, 4, 4431-4436.
10. Bloland, P. B. Drug Resistance in Malaria. Malaria epidemiology branch, centers for disease control and prevention. World Health Organization, 2001, pp. 1-23.
11. Foley, M.; Tilley, L. Quinoline antimalarials: mechanisms of action and resistance and prospects for new agents. Pharmacol. Ther., 1998, 79, 55-87.
12. Chadwick, J.; Mercer, A. E.; Park, B. K.; Cosstick, R.; O'Neill, P. M. Synthesis and biological evaluation of extraordinarily potent C-10 carba artemisinin dimers against P. falciparum malaria parasites and HL-60 cancer cells. Bioorg. Med. Chem., 2009, 17, 1325-1338.
13. Dondorp, A. M.; Nosten, F.; Yi, P.; Das, D.; Phyo, A. P.; Tarning, J.; Lwin, K. M.; Ariey, F.; Hanpithakpong, W.; Lee, S. J.; Ringwald, P.; Silamut, K.; Imwong, M.; Chotivanich, K.; Lim, P.; Herdman, T.; An, S. S.; Yeung, S.; Singhasivanon, P.; Day, N. P.; Lindegardh, N.; Socheat, D.; White, N. J. Artemisinin resistance in Plasmodium falciparum malaria. N. Engl. J. Med., 2009, 361, 455-467.
14. Dondorp, A. M.; Yeung, S.; White, L.; Nguon, C.; Day, N. P.; Socheat, D.; von Seidlein, L. Artemisinin resistance: current status and scenarios for containment. Nat. Rev. Microbiol., 2010, 8, 272-280.
15. Noedl, H.; Se, Y.; Schaecher, K.; Smith, B. L.; Socheat, D.; Fukuda, M. M. Evidence of artemisinin-resistant malaria in western Cambodia. N. Engl. J. Med., 2008, 359, 2619-2620.
16. Noedl, H.; Socheat, D.; Satimai, W. Artemisinin-resistant malaria in Asia. N. Engl. J. Med., 2009, 361, 540-541.
17. Rosenthal, P. J. Antimalarial drug discovery: old and new approaches. J. Exp. Biol., 2003, 206, 3735-3744.
18. Kelly, J. X.; Smilkstein, M. J.; Cooper, R. A.; Lane, K. D.; Johnson, R. A.; Janowsky, A.; Dodean, R. A.; Hinrichs, D. J.; Winter, R.; Riscoe, M. Design, synthesis, and evaluation of 10-N-substituted acridones as novel chemosensitizers in Plasmodium falciparum. Antimicrob. Agents Chemother., 2007, 51, 4133-4140.
19. Burgess, S. J.; Selzer, A.; Kelly, J. X.; Smilkstein, M. J.; Riscoe, M. K.; Peyton, D. H. A chloroquine-like molecule designed to reverse resistance in Plasmodium falciparum. J. Med. Chem., 2006, 49, 5623-5625.
20. Gardner, M. J.; Hall, N.; Fung, E.; White, O.; Berriman, M.; Hyman, R. W.; Carlton, J. M.; Pain, A.; Nelson, K. E.; Bowman, S.; Paulsen, I. T.; James, K.; Eisen, J. A.; Rutherford, K.; Salzberg, S. L.; Craig, A.; Kyes, S.; Chan, M. S.; Nene, V.; Shallom, S. J.; Suh, B.; Peterson, J.; Angiuoli, S.; Pertea, M.; Allen, J.; Selengut, J.; Haft, D.; Mather, M. W.; Vaidya, A. B.; Martin, D. M.; Fairlamb, A. H.; Fraunholz, M. J.; Roos, D. S.; Ralph, S. A.; McFadden, G. I.; Cummings, L. M.; Subramanian, G. M.; Mungall, C.; Venter, J. C.; Carucci, D. J.; Hoffman, S. L.; Newbold, C.; Davis, R. W.; Fraser, C. M.; Barrell, B. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 2002, 419, 498-511.
21. Rosenthal, P. J.; Sijwali, P. S.; Singh, A.; Shenai, B. R. Cysteine proteases of malaria parasites: targets for chemotherapy. Curr. Pharm. Des., 2002, 8, 1659-1672.
22. Sijwali, P. S.; Brinen, L. S.; Rosenthal, P. J. Systematic optimization of expression and refolding of the Plasmodium falciparum cysteine protease falcipain-2. Protein Expr. Purif., 2001, 22, 128-134.
23. Sijwali, P. S.; Shenai, B. R.; Gut, J.; Singh, A.; Rosenthal, P. J. Expression and characterization of the Plasmodium falciparum haemoglobinase falcipain-3. Biochem. J., 2001, 360, 481-489.
24. Eksi, S.; Czesny, B.; van Gemert, G. J.; Sauerwein, R. W.; Eling, W.; Williamson, K. C. Inhibition of Plasmodium falciparum oocyst production by membrane-permeant cysteine protease inhibitor E64d. Antimicrob. Agents Chemother., 2007, 51, 1064-1070.
25. Olson, J. E.; Lee, G. K.; Semenov, A.; Rosenthal, P. J. Antimalarial effects in mice of orally administered peptidyl cysteine protease inhibitors. Bioorg. Med. Chem., 1999, 7, 633-638.
26. Biot, C.; Pradines, B.; Sergeant, M. H.; Gut, J.; Rosenthal, P. J.; Chibale, K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg Med. Chem. Lett., 2007, 17, 6434-6438.
27. Gupta, D.; Yedidi, R. S.; Varghese, S.; Kovari, L. C.; Woster, P. M. Mechanism-based inhibitors of the aspartyl protease plasmepsin II as potential antimalarial agents. J. Med. Chem., 2010, 53, 4234-4247.
28. Padmanaban, G.; Nagaraj, A. G.; Rangarajan, P. N. Drugs and Drug targets against malaria. Curr. Sci. India, 2007, 1545-1555.
29. Phillips, M. A.; Rathod, P. K. Plasmodium dihydroorotate dehydrogenase: a promising target for novel anti-malarial chemotherapy. Infect. Disord. Drug Targets, 2010, 10, 226-239.
30. Baldwin, J.; Farajallah, A. M.; Malmquist, N. A.; Rathod, P. K.; Phillips, M. A. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J. Biol. Chem., 2002, 277, 41827-41834.
31. Patel, V.; Booker, M.; Kramer, M.; Ross, L.; Celatka, C. A.; Kennedy, L. M.; Dvorin, J. D.; Duraisingh, M. T.; Sliz, P.; Wirth, D. F.; Clardy, J. Identification and characterization of small molecule inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem., 2008, 283, 35078-35085.
32. Morgan, D. O. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu. Rev. Cell Dev. Biol., 1997, 13, 261-291.
33. Keenan, S. M.; Geyer, J. A.; Welsh, W. J.; Prigge, S. T.; Waters, N. C. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb. Chem. High Throughput Screen., 2005, 8, 27-38.
34. Waters, N. C.; Geyer, J. A. Cyclin-dependent protein kinases as therapeutic drug targets for antimalarial drug development. Expert Opin. Ther. Targets, 2003, 7, 7-17.
35. Shuttleworth, J. The regulation and functions of cdk7. Prog. Cell Cycle Res., 1995, 1, 229-240.
36. Moskes, C.; Burghaus, P. A.; Wernli, B.; Sauder, U.; Durrenberger, M.; Kappes, B. Export of Plasmodium falciparum calciumdependent protein kinase 1 to the parasitophorous vacuole is dependent on three N-terminal membrane anchor motifs. Mol. Microbiol., 2004, 54, 676-691.
37. Harmon, A. C. Calcium-regulated protein kinases of plants. Gravit. Space Biol. Bull., 2003, 16, 83-90.
38. Kappes, B.; Doerig, C. D.; Graeser, R. An overview of Plasmodium protein kinases. Parasitol. Today, 1999, 15, 449-454.
39. Farber, P. M.; Graeser, R.; Franklin, R. M.; Kappes, B. Molecular cloning and characterization of a second calcium-dependent protein kinase of Plasmodium falciparum. Mol. Biochem. Parasitol., 1997, 87, 211-216. (Pubitemid 27283283)
40. Billker, O.; Dechamps, S.; Tewari, R.; Wenig, G.; Franke-Fayard, B.; Brinkmann, V. Calcium and a calcium-dependent protein kinase regulate gamete formation and mosquito transmission in a malaria parasite. Cell, 2004, 117, 503-514.
41. Andrews, K. T.; Tran, T. N.; Wheatley, N. C.; Fairlie, D. P. Targeting histone deacetylase inhibitors for anti-malarial therapy. Curr. Top. Med. Chem., 2009, 9, 292-308.
42. Davioud-Charvet, E.; Delarue, S.; Biot, C.; Schwobel, B.; Boehme, C. C.; Mussigbrodt, A.; Maes, L.; Sergheraert, C.; Grellier, P.; Schirmer, R. H.; Becker, K. A prodrug form of a Plasmodium falciparum glutathione reductase inhibitor conjugated with a 4-anilinoquinoline. J. Med. Chem., 2001, 44, 4268-4276.
43. Dubois, V. L.; Platel, D. F.; Pauly, G.; Tribouley-Duret, J. Plasmodium berghei: implication of intracellular glutathione and its related enzyme in chloroquine resistance in vivo. Exp. Parasitol., 1995, 81, 117-124.
44. Famin, O.; Krugliak, M.; Ginsburg, H. Kinetics of inhibition of glutathione-mediated degradation of ferriprotoporphyrin IX by antimalarial drugs. Biochem. Pharmacol., 1999, 58, 59-68.
45. Srivastava, I. K.; Morrisey, J. M.; Darrouzet, E.; Daldal, F.; Vaidya, A. B. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol., 1999, 33, 704-711.
46. Ahmad, R.; Srivastava, A. K. Effect of Plasmodium yoelii nigeriensis infection on hepatic and splenic glutathione-S-transferase (s) in Swiss albino and db/+ mice: efficacy of mefloquine and menadione in antimalarial chemotherapy. Parasitology, 2007, 134, 931-938.
47. Hayes, J. D.; Strange, R. C. Potential contribution of the glutathione S-transferase supergene family to resistance to oxidative stress. Free Radic. Res., 1995, 22, 193-207.
48. McFadden, G. I.; Roos, D. S. Apicomplexan plastids as drug targets. Trends Microbiol., 1999, 7, 328-333.
49. Raghu Ram, E. V.; Kumar, A.; Biswas, S.; Kumar, A.; Chaubey, S.; Siddiqi, M. I.; Habib, S. Nuclear gyrB encodes a functional subunit of the Plasmodium falciparum gyrase that is involved in apicoplast DNA replication. Mol. Biochem. Parasitol., 2007, 154, 30-39.
50. Gardner, M. J.; Tettelin, H.; Carucci, D. J.; Cummings, L. M.; Aravind, L.; Koonin, E. V.; Shallom, S.; Mason, T.; Yu, K.; Fujii, C.; Pederson, J.; Shen, K.; Jing, J.; Aston, C.; Lai, Z.; Schwartz, D. C.; Pertea, M.; Salzberg, S.; Zhou, L.; Sutton, G. G.; Clayton, R.; White, O.; Smith, H. O.; Fraser, C. M.; Adams, M. D.; Venter, J. C.; Hoffman, S. L. Chromosome 2 sequence of the human malaria parasite Plasmodium falciparum. Science, 1998, 282, 1126-1132.
51. Harwood, J. L. Recent advances in the biosynthesis of plant fatty acids. Biochim. Biophys. Acta, 1996, 1301, 7-56.
52. Waller, R. F.; Keeling, P. J.; Donald, R. G.; Striepen, B.; Handman, E.; Lang-Unnasch, N.; Cowman, A. F.; Besra, G. S.; Roos, D. S.; McFadden, G. I. Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A., 1998, 95, 12352-12357.
53. Waller, R. F.; Ralph, S. A.; Reed, M. B.; Su, V.; Douglas, J. D.; Minnikin, D. E.; Cowman, A. F.; Besra, G. S.; McFadden, G. I. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob. Agents Chemother, 2003, 47, 297-301.
54. Surolia, N.; Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med., 2001, 7, 167-173.
55. Campbell, J. W.; Cronan, J. E., Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol., 2001, 55, 305-332.
56. McLeod, R.; Muench, S. P.; Rafferty, J. B.; Kyle, D. E.; Mui, E. J.; Kirisits, M. J.; Mack, D. G.; Roberts, C. W.; Samuel, B. U.; Lyons, R. E.; Dorris, M.; Milhous, W. K.; Rice, D. W. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int. J. Parasitol., 2001, 31, 109-113.
57. Perozzo, R.; Kuo, M.; Sidhu, A. S.; Valiyaveettil, J. T.; Bittman, R.; Jacobs, W. R., Jr.; Fidock, D. A.; Sacchettini, J. C. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J. Biol. Chem., 2002, 277, 13106-13114.
58. Jomaa, H.; Wiesner, J.; Sanderbrand, S.; Altincicek, B.; Weidemeyer, C.; Hintz, M.; Turbachova, I.; Eberl, M.; Zeidler, J.; Lichtenthaler, H. K.; Soldati, D.; Beck, E. Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science, 1999, 285, 1573-1576.
59. Ralph, S. A.; van Dooren, G. G.; Waller, R. F.; Crawford, M. J.; Fraunholz, M. J.; Foth, B. J.; Tonkin, C. J.; Roos, D. S.; McFadden, G. I. Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat. Rev. Microbiol., 2004, 2, 203-216.
60. Wilson, R. J. M. Parasite plastids: approaching the endgame. Biol. Rev., 2005, 80, 129-153.
61. Missinou, M. A.; Borrmann, S.; Schindler, A.; Issifou, S.; Adegnika, A. A.; Matsiegui, P. B.; Binder, R.; Lell, B.; Wiesner, J.; Baranek, T.; Jomaa, H.; Kremsner, P. G. Fosmidomycin for malaria. Lancet, 2002, 360, 1941-1942.
62. Lell, B.; Ruangweerayut, R.; Wiesner, J.; Missinou, M. A.; Schindler, A.; Baranek, T.; Hintz, M.; Hutchinson, D.; Jomaa, H.; Kremsner, P. G. Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob. Agents Chemother., 2003, 47, 735-738.
63. Wiesner, J.; Borrmann, S.; Jomaa, H. Fosmidomycin for the treatment of malaria. Parasitol. Res., 2003, 90 Suppl 2, S71-76.
64. Surolia, N.; Padmanaban, G. de novo biosynthesis of heme offers a new chemotherapeutic target in the human malarial parasite. Biochem. Biophys. Res. Commun., 1992, 187, 744-750.
65. Bonday, Z. Q.; Dhanasekaran, S.; Rangarajan, P. N.; Padmanaban, G. Import of host delta-aminolevulinate dehydratase into the malarial parasite: identification of a new drug target. Nat. Med., 2000, 6, 898-903.
66. Varadharajan, S.; Sagar, B. K.; Rangarajan, P. N.; Padmanaban, G. Localization of ferrochelatase in Plasmodium falciparum. Biochem. J., 2004, 384, 429-436.
67. Sato, S.; Wilson, R. J. The genome of Plasmodium falciparum encodes an active delta-aminolevulinic acid dehydratase. Curr. Genet., 2002, 40, 391-398.
68. van Dooren, G. G.; Su, V.; D'Ombrain, M. C.; McFadden, G. I. Processing of an apicoplast leader sequence in Plasmodium falciparum and the identification of a putative leader cleavage enzyme. J. Biol. Chem., 2002, 277, 23612-23619.
69. Varadharajan, S.; Dhanasekaran, S.; Bonday, Z. Q.; Rangarajan, P. N.; Padmanaban, G. Involvement of delta-aminolaevulinate synthase encoded by the parasite gene in de novo haem synthesis by Plasmodium falciparum. Biochem. J., 2002, 367, 321-327.
70. Dhanasekaran, S.; Chandra, N. R.; Chandrasekhar Sagar, B. K.; Rangarajan, P. N.; Padmanaban, G. Delta-aminolevulinic acid dehydratase from Plasmodium falciparum: indigenous versus imported. J. Biol. Chem., 2004, 279, 6934-6942.
71. Sato, S.; Clough, B.; Coates, L.; Wilson, R. J. Enzymes for heme biosynthesis are found in both the mitochondrion and plastid of the malaria parasite Plasmodium falciparum. Protist, 2004, 155, 117-125.
72. Feagin, J. E.; Drew, M. E. Plasmodium falciparum: alterations in organelle transcript abundance during the erythrocytic cycle. Exp. Parasitol., 1995, 80, 430-440.
73. Wilson, C. M.; Smith, A. B.; Baylon, R. V. Characterization of the delta-aminolevulinate synthase gene homologue in P. falciparum. Mol. Biochem. Parasitol., 1996, 79, 135-140.
74. Wilson, R. J.; Denny, P. W.; Preiser, P. R.; Rangachari, K.; Roberts, K.; Roy, A.; Whyte, A.; Strath, M.; Moore, D. J.; Moore, P. W.; Williamson, D. H. Complete gene map of the plastid-like DNA of the malaria parasite Plasmodium falciparum. J. Mol. Biol., 1996, 261, 155-172.
75. Clough, B.; Rangachari, K.; Strath, M.; Preiser, P. R.; Wilson, R. J. Antibiotic inhibitors of organellar protein synthesis in Plasmodium falciparum. Protist, 1999, 150, 189-195.
76. Roy, A.; Cox, R. A.; Williamson, D. H.; Wilson, R. J. Protein synthesis in the plastid of Plasmodium falciparum. Protist, 1999, 150, 183-188.
77. Kohler, S.; Delwiche, C. F.; Denny, P. W.; Tilney, L. G.; Webster, P.; Wilson, R. J.; Palmer, J. D.; Roos, D. S. A plastid of probable green algal origin in Apicomplexan parasites. Science, 1997, 275, 1485-1489.
78. Williamson, K. C.; Fujioka, H.; Aikawa, M.; Kaslow, D. C. Stagespecific processing of Pfs230, a Plasmodium falciparum transmission-blocking vaccine candidate. Mol. Biochem. Parasitol., 1996, 78, 161-169.
79. Divo, A. A.; Sartorelli, A. C.; Patton, C. L.; Bia, F. J. Activity of fluoroquinolone antibiotics against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother., 1988, 32, 1182-1186.
80. Weissig, V.; Vetro-Widenhouse, T. S.; Rowe, T. C. Topoisomerase II inhibitors induce cleavage of nuclear and 35-kb plastid DNAs in the malarial parasite Plasmodium falciparum. DNA Cell Biol., 1997, 16, 1483-1492.
81. Fichera, M. E.; Roos, D. S. A plastid organelle as a drug target in apicomplexan parasites. Nature, 1997, 390, 407-409.
82. Williamson, D. H.; Preiser, P. R.; Moore, P. W.; McCready, S.; Strath, M.; Wilson, R. J. The plastid DNA of the malaria parasite Plasmodium falciparum is replicated by two mechanisms. Mol. Microbiol., 2002, 45, 533-542.
83. Pennisi, E. Malarial genome comes into view. Science, 1999, 286, 1263;1265.
84. Dar, M. A.; Sharma, A.; Mondal, N.; Dhar, S. K. Molecular cloning of apicoplast-targeted Plasmodium falciparum DNA gyrase genes: unique intrinsic ATPase activity and ATP-independent dimerization of PfGyrB subunit. Eukaryot. Cell., 2007, 6, 398-412.
85. Ali, J. A.; Jackson, A. P.; Howells, A. J.; Maxwell, A. The 43-kilodalton N-terminal fragment of the DNA gyrase B protein hydrolyzes ATP and binds coumarin drugs. Biochemistry, 1993, 32, 2717-2724.
86. Dahl, E. L.; Rosenthal, P. J. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother., 2007, 51, 3485-3490.
87. Khor, V.; Yowell, C.; Dame, J. B.; Rowe, T. C. Expression and characterization of the ATP-binding domain of a malarial Plasmodium vivax gene homologous to the B-subunit of the bacterial topoisomerase DNA gyrase. Mol. Biochem. Parasitol., 2005, 140, 107-117.
88. Ellis, K. E.; Clough, B.; Saldanha, J. W.; Wilson, R. J. Nifs and Sufs in malaria. Mol. Microbiol., 2001, 41, 973-981.
89. Tokumoto, U.; Nomura, S.; Minami, Y.; Mihara, H.; Kato, S.; Kurihara, T.; Esaki, N.; Kanazawa, H.; Matsubara, H.; Takahashi, Y. Network of protein-protein interactions among iron-sulfur cluster assembly proteins in Escherichia coli. J. Biochem., 2002, 131, 713-719.
90. Thomsen-Zieger, N.; Schachtner, J.; Seeber, F. Apicomplexan parasites contain a single lipoic acid synthase located in the plastid. FEBS Lett., 2003, 547, 80-86.
91. Gunther, S.; McMillan, P. J.; Wallace, L. J.; Muller, S. Plasmodium falciparum possesses organelle-specific alpha-keto acid dehydrogenase complexes and lipoylation pathways. Biochem. Soc. Trans., 2005, 33, 977-980.
92. Painter, H. J.; Morrisey, J. M.; Mather, M. W.; Vaidya, A. B. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature, 2007, 446, 88-91.
93. Srivastava, I. K.; Rottenberg, H.; Vaidya, A. B. Atovaquone, a broad spectrum antiparasitic drug, collapses mitochondrial membrane potential in a malarial parasite. J. Biol. Chem., 1997, 272, 3961-3966.
94. Biagini, G. A.; Fisher, N.; Berry, N.; Stocks, P. A.; Meunier, B.; Williams, D. P.; Bonar-Law, R.; Bray, P. G.; Owen, A.; O'Neill, P. M.; Ward, S. A. Acridinediones: selective and potent inhibitors of the malaria parasite mitochondrial bc1 complex. Mol. Pharmacol., 2008, 73, 1347-1355.
95. Nyakeriga, A. M.; Perlmann, H.; Hagstedt, M.; Berzins, K.; Troye-Blomberg, M.; Zhivotovsky, B.; Perlmann, P.; Grandien, A. Druginduced death of the asexual blood stages of Plasmodium falciparum occurs without typical signs of apoptosis. Microbes Infect., 2006, 8, 1560-1568.
96. Crofts, A. R. The cytochrome bc1 complex: function in the context of structure. Annu. Rev. Physiol., 2004, 66, 689-733.
97. Daily, J. P.; Scanfeld, D.; Pochet, N.; Le Roch, K.; Plouffe, D.; Kamal, M.; Sarr, O.; Mboup, S.; Ndir, O.; Wypij, D.; Levasseur, K.; Thomas, E.; Tamayo, P.; Dong, C.; Zhou, Y.; Lander, E. S.; Ndiaye, D.; Wirth, D.; Winzeler, E. A.; Mesirov, J. P.; Regev, A. Distinct physiological states of Plasmodium falciparum in malariainfected patients. Nature, 2007, 450, 1091-1095.
98. van Dooren, G. G.; McFadden, G. I. Malaria: differential parasite drive. Nature, 2007, 450, 955-956.
99. Araujo, N. C.; Barton, V.; Jones, M.; Stocks, P. A.; Ward, S. A.; Davies, J.; Bray, P. G.; Shone, A. E.; Cristiano, M. L.; O'Neill, P. M. Semi-synthetic and synthetic 1, 2, 4-trioxaquines and 1, 2, 4-trioxolaquines: synthesis, preliminary SAR and comparison with acridine endoperoxide conjugates. Bioorg. Med. Chem. Lett., 2009, 19, 2038-2043.
100. Allen, R. T.; Hunter, W. J., 3rd; Agrawal, D. K. Morphological and biochemical characterization and analysis of apoptosis. J. Pharmacol. Toxicol. Methods, 1997, 37, 215-228.
101. Ziegler, U.; Groscurth, P. Morphological features of cell death. News Physiol. Sci., 2004, 19, 124-128.
102. Holubec, H.; Payne, C. M.; Bernstein, H.; Dvorakova, K.; Bernstein, C.; Waltmire, C. N.; Warneke, J. A.; Garewal, H. Assessment of apoptosis by immunohistochemical markers compared to cellular morphology in ex vivo-stressed colonic mucosa. J. Histochem. Cytochem., 2005, 53, 229-235.
103. Garrity, M. M.; Burgart, L. J.; Riehle, D. L.; Hill, E. M.; Sebo, T. J.; Witzig, T. Identifying and quantifying apoptosis: navigating technical pitfalls. Mod. Pathol., 2003, 16, 389-394.
104. Nasirudeen, A. M.; Hian, Y. E.; Singh, M.; Tan, K. S. Metronidazole induces programmed cell death in the protozoan parasite Blastocystis hominis. Microbiology, 2004, 150, 33-43.
105. Villalba, J. D.; Gomez, C.; Medel, O.; Sanchez, V.; Carrero, J. C.; Shibayama, M.; Ishiwara, D. G. Programmed cell death in Entamoeba histolytica induced by the aminoglycoside G418. Microbiology, 2007, 153, 3852-3863. (Pubitemid 350168264)
106. Abend, M.; Schmelz, H. U.; Kraft, K.; Rhein, A. P.; van Beuningen, D.; Sparwasser, C. Intercomparison of apoptosis morphology with active DNA cleavage on single cells in vitro and on testis tumours. J. Pathol., 1998, 185, 419-426.
107. Abend, M.; Schmelz, H. U.; Kraft, K.; van Beuningen, D.; Sparwasser, C. Modified approach for apoptosis detection reveals changes in apoptotic processes in the seminoma-associated tissue. Apoptosis, 1999, 4, 283-290.
108. Formigli, L.; Papucci, L.; Tani, A.; Schiavone, N.; Tempestini, A.; Orlandini, G. E.; Capaccioli, S.; Orlandini, S. Z. Aponecrosis: morphological and biochemical exploration of a syncretic process of cell death sharing apoptosis and necrosis. J. Cell Physiol., 2000, 182, 41-49.
109. Nguewa, P. A.; Fuertes, M. A.; Valladares, B.; Alonso, C.; Perez, J. M. Programmed cell death in trypanosomatids: a way to maximize their biological fitness? Trends Parasitol., 2004, 20, 375-380.
110. Zangger, H.; Mottram, J. C.; Fasel, N. Cell death in Leishmania induced by stress and differentiation: programmed cell death or necrosis? Cell Death Differ., 2002, 9, 1126-1139.
111. Uren, A. G.; O'Rourke, K.; Aravind, L. A.; Pisabarro, M. T.; Seshagiri, S.; Koonin, E. V.; Dixit, V. M. Identification of paracaspases and metacaspases: two ancient families of caspase-like proteins, one of which plays a key role in MALT lymphoma. Mol. Cell., 2000, 6, 961-967.
112. Schwab, B. L.; Guerini, D.; Didszun, C.; Bano, D.; Ferrando-May, E.; Fava, E.; Tam, J.; Xu, D.; Xanthoudakis, S.; Nicholson, D. W.; Carafoli, E.; Nicotera, P. Cleavage of plasma membrane calcium pumps by caspases: a link between apoptosis and necrosis. Cell Death Differ., 2002, 9, 818-831.
113. Nguewa, P. A.; Fuertes, M. A.; Cepeda, V.; Alonso, C.; Quevedo, C.; Soto, M.; Perez, J. M. Poly (ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med. Chem., 2006, 2, 47-53.
114. Holzmuller, P.; Sereno, D.; Cavaleyra, M.; Mangot, I.; Daulouede, S.; Vincendeau, P.; Lemesre, J. L. Nitric oxide-mediated proteasome-dependent oligonucleosomal DNA fragmentation in Leishmania amazonensis amastigotes. Infect. Immun., 2002, 70, 3727-3735.
115. De Souza, E. M.; Menna-Barreto, R.; Araujo-Jorge, T. C.; Kumar, A.; Hu, Q.; Boykin, D. W.; Soeiro, M. N. Antiparasitic activity of aromatic diamidines is related to apoptosis-like death in Trypanosoma cruzi. Parasitology, 2006, 133, 75-79.
116. Chose, O.; Sarde, C. O.; Noel, C.; Gerbod, D.; Jimenez, J. C.; Brenner, C.; Capron, M.; Viscogliosi, E.; Roseto, A. Cell death in protists without mitochondria. Ann. N. Y. Acad. Sci., 2003, 1010, 121-125.
117. Christensen, S. T.; Wheatley, D. N.; Rasmussen, M. I.; Rasmussen, L. Mechanisms controlling death, survival and proliferation in a model unicellular eukaryote Tetrahymena thermophila. Cell Death Differ., 1995, 2, 301-308.
118. Kobayashi, T.; Endoh, H. Caspase-like activity in programmed nuclear death during conjugation of Tetrahymena thermophila. Cell Death Differ., 2003, 10, 634-640.
119. Nasirudeen, A. M.; Singh, M.; Yap, E. H.; Tan, K. S. Blastocystis hominis: evidence for caspase-3-like activity in cells undergoing programmed cell death. Parasitol. Res., 2001, 87, 559-565.
120. Nasirudeen, A. M.; Tan, K. S.; Singh, M.; Yap, E. H. Programmed cell death in a human intestinal parasite, Blastocystis hominis. Parasitology, 2001, 123, 235-246. (Pubitemid 32881848)
121. Picot, S.; Burnod, J.; Bracchi, V.; Chumpitazi, B. F.; Ambroise-Thomas, P. Apoptosis related to chloroquine sensitivity of the human malaria parasite Plasmodium falciparum. Trans. R. Soc. Trop. Med. Hyg., 1997, 91, 590-591.
122. Al-Olayan, E. M.; Williams, G. T.; Hurd, H. Apoptosis in the malaria protozoan, Plasmodium berghei: a possible mechanism for limiting intensity of infection in the mosquito. Int. J. Parasitol., 2002, 32, 1133-1143.
123. Meslin, B.; Barnadas, C.; Boni, V.; Latour, C.; De Monbrison, F.; Kaiser, K.; Picot, S. Features of apoptosis in Plasmodium falciparum erythrocytic stage through a putative role of PfMCA1 metacaspase-like protein. J. Infect. Dis., 2007, 195, 1852-1859.
124. Lewis, K. Programmed death in bacteria. Microbiol. Mol. Biol. Rev., 2000, 64, 503-514.
125. Sat, B.; Hazan, R.; Fisher, T.; Khaner, H.; Glaser, G.; Engelberg-Kulka, H. Programmed cell death in Escherichia coli: some antibiotics can trigger mazEF lethality. J. Bacteriol., 2001, 183, 2041-2045.
126. Madeo, F.; Frohlich, E.; Ligr, M.; Grey, M.; Sigrist, S. J.; Wolf, D. H.; Frohlich, K. U. Oxygen stress: a regulator of apoptosis in yeast. J. Cell Biol., 1999, 145, 757-767.
127. Cornillon, S.; Foa, C.; Davoust, J.; Buonavista, N.; Gross, J. D.; Golstein, P. Programmed cell death in Dictyostelium. J. Cell Sci., 1994, 107, 2691-2704.
128. Vardi, A.; Berman-Frank, I.; Rozenberg, T.; Hadas, O.; Kaplan, A.; Levine, A. Programmed cell death of the dinoflagellate Peridinium gatunense is mediated by CO[2]limitation and oxidative stress. Curr. Biol., 1999, 9, 1061-1064.
129. Scheuerlein, R.; Treml, S.; Thar, B.; Tirlapur, U. K.; Hader, D. P. Evidence for UV-B-induced DNA degradation in Euglena gracilis mediated by activation of metal-dependent nucleases. J. Photochem. Photobiol. B., 1995, 31, 113-123.
130. Bruchhaus, I.; Loftus, B. J.; Hall, N.; Tannich, E. The intestinal protozoan parasite Entamoeba histolytica contains 20 cysteine protease genes, of which only a small subset is expressed during in vitro cultivation. Eukaryot. Cell, 2003, 2, 501-509.
131. Tillack, M.; Biller, L.; Irmer, H.; Freitas, M.; Gomes, M. A.; Tannich, E.; Bruchhaus, I. The Entamoeba histolytica genome: primary structure and expression of proteolytic enzymes. BMC Genomics, 2007, 8, 170.
132. Ramos, E.; Olivos-Garcia, A.; Nequiz, M.; Saavedra, E.; Tello, E.; Saralegui, A.; Montfort, I.; Perez Tamayo, R. Entamoeba histolytica: apoptosis induced in vitro by nitric oxide species. Exp. Parasitol., 2007, 116, 257-265.
133. Sen, N.; Das, B. B.; Ganguly, A.; Mukherjee, T.; Bandyopadhyay, S.; Majumder, H. K. Camptothecin-induced imbalance in intracellular cation homeostasis regulates programmed cell death in unicellular hemoflagellate Leishmania donovani. J. Biol. Chem., 2004, 279, 52366-52375. (Pubitemid 39656613)
134. Sen, N.; Das, B. B.; Ganguly, A.; Mukherjee, T.; Tripathi, G.; Bandyopadhyay, S.; Rakshit, S.; Sen, T.; Majumder, H. K. Camptothecin induced mitochondrial dysfunction leading to programmed cell death in unicellular hemoflagellate Leishmania donovani. Cell Death Differ., 2004, 11, 924-936. (Pubitemid 39139751)
135. Lee, N.; Bertholet, S.; Debrabant, A.; Muller, J.; Duncan, R.; Nakhasi, H. L. Programmed cell death in the unicellular protozoan parasite Leishmania. Cell Death Differ., 2002, 9, 53-64.
136. Soeiro, M. N.; De Souza, E. M.; Stephens, C. E.; Boykin, D. W. Aromatic diamidines as antiparasitic agents. Expert Opin. Investig. Drugs, 2005, 14, 957-972.
137. Szallies, A.; Kubata, B. K.; Duszenko, M. A metacaspase of Trypanosoma brucei causes loss of respiration competence and clonal death in the yeast Saccharomyces cerevisiae. FEBS Lett., 2002, 517, 144-150.
138. Nguewa, P. A.; Fuertes, M. A.; Alonso, C.; Perez, J. M. Pharmacological modulation of Poly (ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy. Mol. Pharmacol., 2003, 64, 1007-1014.
139. Welburn, S. C.; Barcinski, M. A.; Williams, G. T. Programmed cell death in trypanosomatids. Parasitol. Today, 1997, 13, 22-26.
140. Deponte, M.; Becker, K. Plasmodium falciparum-do killers commit suicide? Trends Parasitol., 2004, 20, 165-169.
141. Matsuyama, S.; Llopis, J.; Deveraux, Q. L.; Tsien, R. Y.; Reed, J. C. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat. Cell Biol., 2000, 2, 318-325.
142. Matsuyama, S.; Reed, J. C. Mitochondria-dependent apoptosis and cellular pH regulation. Cell Death Differ, 2000, 7, 1155-1165.
143. Totino, P. R.; Daniel-Ribeiro, C. T.; Corte-Real, S.; de Fatima Ferreira-da-Cruz, M. Plasmodium falciparum: erythrocytic stages die by autophagic-like cell death under drug pressure. Exp. Parasitol., 2008, 118, 478-486.
144. Jensen, J. B.; Boland, M. T.; Akood, M. Induction of crisis forms in cultured Plasmodium falciparum with human immune serum from Sudan. Science, 1982, 216, 1230-1233.
145. Carlin, J. M.; Jensen, J. B.; Geary, T. G. Comparison of inducers of crisis forms in Plasmodium falciparum in vitro. Am. J. Trop. Med. Hyg., 1985, 34, 668-674.
146. Yi, A. K.; Peckham, D. W.; Ashman, R. F.; Krieg, A. M. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. Int. Immunol., 1999, 11, 2015-2024.
147. Lagneaux, L.; Delforge, A.; Carlier, S.; Massy, M.; Bernier, M.; Bron, D. Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors. Br. J. Haematol., 2001, 112, 344-352.
148. Wolbers, F.; Buijtenhuijs, P.; Haanen, C.; Vermes, H. Apoptotic cell death kinetics in vitro depend on the cell types and the inducers used. Apoptosis, 2004, 9, 385-392.
149. Wu, Y.; Wang, X.; Liu, X.; Wang, Y. Data-mining approaches reveal hidden families of proteases in the genome of malaria parasite. Genome Res., 2003, 13, 601-616.
150. Rathod, P. K.; Khatri, A.; Hubbert, T.; Milhous, W. K. Selective activity of 5-fluoroorotic acid against Plasmodium falciparum in vitro. Antimicrob. Agents Chemother., 1989, 33, 1090-1094.
151. Rathod, P. K.; Leffers, N. P.; Young, R. D. Molecular targets of 5-fluoroorotate in the human malaria parasite, Plasmodium falciparum. Antimicrob. Agents Chemother., 1992, 36, 704-711.
152. Muregi, F. W.; Kano, S.; Kino, H.; Ishih, A. Plasmodium berghei: efficacy of 5-fluoroorotate in combination with commonly used antimalarial drugs in a mouse model. Exp. Parasitol., 2009, 121, 376-380.
153. Hurd, H.; Grant, K. M.; Arambage, S. C. Apoptosis-like death as a feature of malaria infection in mosquitoes. Parasitology, 2006, 132 Suppl, S33-47.
154. Sinden, R. E. The biology of Plasmodium in the mosquito. Experientia, 1984, 40, 1330-1343.
155. Sinden, R. E. Molecular interactions between Plasmodium and its insect vectors. Cell Microbiol., 2002, 4, 713-724.
156. Sinden, R. E.; Butcher, G. A.; Beetsma, A. L. Maintenance of the Plasmodium berghei life cycle. Methods Mol. Med., 2002, 72, 25-40.
157. Vaughan, J. A.; Narum, D.; Azad, A. F. Plasmodium berghei ookinete densities in three anopheline species. J. Parasitol., 1991, 77, 758-761.
158. Beier, J. C. Malaria parasite development in mosquitoes. Annu. Rev. Entomol., 1998, 43, 519-543.
159. Ghosh, A.; Edwards, M. J.; Jacobs-Lorena, M. The journey of the malaria parasite in the mosquito: hopes for the new century. Parasitol. Today, 2000, 16, 196-201.
160. Billingsley, P. F.; Sinden, R. E. Determinants of malaria-mosquito specificity. Parasitol. Today, 1997, 13, 297-301.
161. Sinden, R. E.; Billingsley, P. F. Plasmodium invasion of mosquito cells: hawk or dove? Trends Parasitol., 2001, 17, 209-212.
162. Aravind, L.; Dixit, V. M.; Koonin, E. V. Apoptotic molecular machinery: vastly increased complexity in vertebrates revealed by genome comparisons. Science, 2001, 291, 1279-1284.
163. Rosenthal, P. J. Cysteine proteases of malaria parasites. Int. J. Parasitol., 2004, 34, 1489-1499.
164. Le Chat, L.; Sinden, R. E.; Dessens, J. T. The role of metacaspase 1 in Plasmodium berghei development and apoptosis. Mol. Biochem. Parasitol., 2007, 153, 41-47.
165. Madeo, F.; Herker, E.; Maldener, C.; Wissing, S.; Lachelt, S.; Herlan, M.; Fehr, M.; Lauber, K.; Sigrist, S. J.; Wesselborg, S.; Frohlich, K. U. A caspase-related protease regulates apoptosis in yeast. Mol. Cell, 2002, 9, 911-917.
166. Mazzoni, C.; Herker, E.; Palermo, V.; Jungwirth, H.; Eisenberg, T.; Madeo, F.; Falcone, C. Yeast caspase 1 links messenger RNA stability to apoptosis in yeast. EMBO Rep., 2005, 6, 1076-1081.
167. Squier, M. K.; Cohen, J. J. Calpain, an upstream regulator of thymocyte apoptosis. J. Immunol., 1997, 158, 3690-3697.
168. Blomgren, K.; Zhu, C.; Wang, X.; Karlsson, J. O.; Leverin, A. L.; Bahr, B. A.; Mallard, C.; Hagberg, H. Synergistic activation of caspase-3 by m-calpain after neonatal hypoxia-ischemia: a mechanism of "pathological apoptosis"? J. Biol. Chem., 2001, 276, 10191-10198.
169. Turk, B.; Stoka, V.; Rozman-Pungercar, J.; Cirman, T.; Droga-Mazovec, G.; Oresic, K.; Turk, V. Apoptotic pathways: involvement of lysosomal proteases. Biol. Chem., 2002, 383, 1035-1044.
170. Turk, V.; Turk, B.; Guncar, G.; Turk, D.; Kos, J. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv. Enzyme. Regul, 2002, 42, 285-303.
171. Stoka, V.; Turk, B.; Schendel, S. L.; Kim, T. H.; Cirman, T.; Snipas, S. J.; Ellerby, L. M.; Bredesen, D.; Freeze, H.; Abrahamson, M.; Bromme, D.; Krajewski, S.; Reed, J. C.; Yin, X. M.; Turk, V.; Salvesen, G. S. Lysosomal protease pathways to apoptosis. Cleavage of bid, not pro-caspases, is the most likely route. J. Biol. Chem., 2001, 276, 3149-3157.
172. Bursch, W. The autophagosomal-lysosomal compartment in programmed cell death. Cell Death Differ., 2001, 8, 569-581.
173. Ameisen, J. C. On the origin, evolution, and nature of programmed cell death: a timeline of four billion years. Cell Death Differ., 2002, 9, 367-393.
174. Manuel, J.; Pérez Martín, P., Eds; Programmed cell death in protozoa; Landes Bioscience, Springer: New York, U. S. A., 2008.
175. Kim, R.; Tanabe, K.; Uchida, Y.; Emi, M.; Inoue, H.; Toge, T. Current status of the molecular mechanisms of anticancer druginduced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy. Cancer Chemother. Pharmacol., 2002, 50, 343-352.
176. Debrabant, A.; Lee, N.; Bertholet, S.; Duncan, R.; Nakhasi, H. L. Programmed cell death in trypanosomatids and other unicellular organisms. Int. J. Parasitol., 2003, 33, 257-267.
177. Murphy, M. P. Nitric oxide and cell death. Biochim. Biophys. Acta, 1999, 1411, 401-414.
178. Bortner, C.; Cidlowski, J. A. Sodium uptake is required for apoptotic cell shrinkage during anti-Fas induced apoptosis. Cytometry, 2002, 78-78.
179. Bortner, C. D.; Hughes, F. M., Jr.; Cidlowski, J. A. A primary role for K+ and Na+ efflux in the activation of apoptosis. J. Biol. Chem., 1997, 272, 32436-32442.
180. Meshnick, S. R.; Thomas, A.; Ranz, A.; Xu, C. M.; Pan, H. Z. Artemisinin[qinghaosu]: the role of intracellular hemin in its mechanism of antimalarial action. Mol. Biochem. Parasitol., 1991, 49, 181-189.
181. Meshnick, S. R.; Yang, Y. Z.; Lima, V.; Kuypers, F.; Kamchonwongpaisan, S.; Yuthavong, Y. Iron-dependent free radical generation from the antimalarial agent artemisinin (qinghaosu). Antimicrob. Agents Chemother., 1993, 37, 1108-1114.
182. Ellis, D. S.; Li, Z. L.; Gu, H. M.; Peters, W.; Robinson, B. L.; Tovey, G.; Warhurst, D. C. The chemotherapy of rodent malaria, XXXIX. Ultrastructural changes following treatment with artemisinine of Plasmodium berghei infection in mice, with observations of the localization of (3H)-dihydroartemisinine in P. falciparum in vitro. Ann. Trop. Med. Parasitol., 1985, 79, 367-374.
183. Kawai, S.; Kano, S.; Suzuki, M. Morphologic effects of artemether on Plasmodium falciparum in Aotus trivirgatus. Am. J. Trop. Med. Hyg., 1993, 49, 812-818.
184. Jiang, J. B.; Jacobs, G.; Liang, D. S.; Aikawa, M. Qinghaosuinduced changes in the morphology of Plasmodium inui. Am. J. Trop. Med. Hyg., 1985, 34, 424-428.
185. Maeno, Y.; Toyoshima, T.; Fujioka, H.; Ito, Y.; Meshnick, S. R.; Benakis, A.; Milhous, W. K.; Aikawa, M. Morphologic effects of artemisinin in Plasmodium falciparum. Am. J. Trop. Med. Hyg., 1993, 49, 485-491.
186. Wang, J.; Huang, L.; Li, J.; Fan, Q.; Long, Y.; Li, Y.; Zhou, B. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One, 2010, 5, e9582.
187. Zhou, H. J.; Wang, Z.; Li, A. Dihydroartemisinin induces apoptosis in human leukemia cells HL60 via downregulation of transferrin receptor expression. Anticancer Drugs, 2008, 19, 247-255.
188. May, W. S. Jr.; Cuatrecasas, P. Transferrin receptor: its biological significance. J. Membr. Biol., 1985, 88, 205-215.
189. O'Donnell, K. A.; Yu, D.; Zeller, K. I.; Kim, J. W.; Racke, F.; Thomas-Tikhonenko, A.; Dang, C. V. Activation of transferrin receptor 1 by c-Myc enhances cellular proliferation and tumorigenesis. Mol. Cell Biol., 2006, 26, 2373-2386.
190. Fukuchi, K.; Tomoyasu, S.; Tsuruoka, N.; Gomi, K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett., 1994, 350, 139-142.
191. Truksa, J.; Kovar, J.; Valenta, T.; Ehrlichova, M.; Polak, J.; Naumann, P. W. Iron deprivation induces apoptosis independently of p53 in human and murine tumour cells. Cell Prolif., 2003, 36, 199-213.
192. Atamna, H.; Ginsburg, H. Heme degradation in the presence of glutathione. A proposed mechanism to account for the high levels of non-heme iron found in the membranes of hemoglobinopathic red blood cells. J. Biol. Chem., 1995, 270, 24876-24883.
193. Olliaro, P. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Ther., 2001, 89, 207-219.
194. Francis, S. E.; Sullivan, D. J. Jr.; Goldberg, D. E. Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. Annu. Rev. Microbiol., 1997, 51, 97-123.
195. Zhang, J.; Krugliak, M.; Ginsburg, H. The fate of ferriprotorphyrin IX in malaria infected erythrocytes in conjunction with the mode of action of antimalarial drugs. Mol. Biochem. Parasitol., 1999, 99, 129-141.
196. Malhotra, K.; Salmon, D.; Le Bras, J.; Vilde, J. L. Potentiation of chloroquine activity against Plasmodium falciparum by the peroxidase-hydrogen peroxide system. Antimicrob. Agents Chemother., 1990, 34, 1981-1985.
197. Hyde, J. E. Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect., 2002, 4, 165-174.
198. Schwarz, E.; Neupert, W. Mitochondrial protein import: mechanisms, components and energetics. Biochim. Biophys. Acta, 1994, 1187, 270-274. (Pubitemid 24267069)
199. Zamzami, N.; Marchetti, P.; Castedo, M.; Decaudin, D.; Macho, A.; Hirsch, T.; Susin, S. A.; Petit, P. X.; Mignotte, B.; Kroemer, G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J. Exp. Med., 1995, 182, 367-377.
200. Zamzami, N.; Marchetti, P.; Castedo, M.; Zanin, C.; Vayssiere, J. L.; Petit, P. X.; Kroemer, G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med., 1995, 181, 1661-1672.
201. Zamzami, N.; Marchetti, P.; Castedo, M.; Hirsch, T.; Susin, S. A.; Masse, B.; Kroemer, G. Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett., 1996, 384, 53-57.
202. Zamzami, N.; Susin, S. A.; Marchetti, P.; Hirsch, T.; Gomez-Monterrey, I.; Castedo, M.; Kroemer, G. Mitochondrial control of nuclear apoptosis. J. Exp. Med., 1996, 183, 1533-1544.
203. Deckwerth, T. L.; Johnson, E. M. Jr. Temporal analysis of events associated with programmed cell death (apoptosis) of sympathetic neurons deprived of nerve growth factor. J. Cell Biol., 1993, 123, 1207-1222.
204. Davies, C. S.; Pudney, M.; Matthews, P. J.; Sinden, R. E. The causal prophylactic activity of the novel hydroxynaphthoquinone 566C80 against Plasmodium berghei infections in rats. Acta Leiden., 1989, 58, 115-128.
205. Davies, C. S.; Pudney, M.; Nicholas, J. C.; Sinden, R. E. The novel hydroxynaphthoquinone 566C80 inhibits the development of liver stages of Plasmodium berghei cultured in vitro. Parasitology, 1993, 106, 1-6.
206. Fowler, R. E.; Sinden, R. E.; Pudney, M. Inhibitory activity of the anti-malarial atovaquone (566C80) against ookinetes, oocysts, and sporozoites of Plasmodium berghei. J. Parasitol., 1995, 81, 452-458.
207. Tagliarino, C.; Pink, J. J.; Dubyak, G. R.; Nieminen, A. L.; Boothman, D. A. Calcium is a key signaling molecule in beta-lapachonemediated cell death. J. Biol. Chem., 2001, 276, 19150-19159.
208. Pink, J. J.; Planchon, S. M.; Tagliarino, C.; Varnes, M. E.; Siegel, D.; Boothman, D. A. NAD (P) H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem., 2000, 275, 5416-5424.
209. Pink, J. J.; Wuerzberger-Davis, S.; Tagliarino, C.; Planchon, S. M.; Yang, X.; Froelich, C. J.; Boothman, D. A. Activation of a cysteine protease in MCF-7 and T47D breast cancer cells during betalapachone-mediated apoptosis. Exp. Cell Res., 2000, 255, 144-155.
210. Marin, A.; Lopez de Cerain, A.; Hamilton, E.; Lewis, A. D.; Martinez-Penuela, J. M.; Idoate, M. A.; Bello, J. DT-diaphorase and cytochrome B5 reductase in human lung and breast tumours. B r. J. Cancer, 1997, 76, 923-929.
211. Fuertes, M. A.; Alonso, C.; Perez, J. M. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem. Rev., 2003, 103, 645-662.
212. Lindahl, T.; Satoh, M. S.; Poirier, G. G.; Klungland, A. Posttranslational modification of poly (ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem. Sci., 1995, 20, 405-411.
213. D'Amours, D.; Desnoyers, S.; D'Silva, I.; Poirier, G. G. Poly (ADP-ribosyl) ation reactions in the regulation of nuclear functions. Biochem. J., 1999, 342, 249-268.
214. Martin, D. R.; Lewington, A. J.; Hammerman, M. R.; Padanilam, B. J. Inhibition of poly (ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2000, 279, 1834-1840.
215. Du, L.; Zhang, X.; Han, Y. Y.; Burke, N. A.; Kochanek, P. M.; Watkins, S. C.; Graham, S. H.; Carcillo, J. A.; Szabo, C.; Clark, R. S. Intra-mitochondrial poly (ADP-ribosylation) contributes to NAD+ depletion and cell death induced by oxidative stress. J. Biol. Chem., 2003, 278, 18426-18433.
216. Gonzalez, J.; Harris, T.; Childs, G.; Prystowsky, M. B. Rapamycin blocks IL-2-driven T cell cycle progression while preserving T cell survival. Blood Cells Mol. Dis., 2001, 27, 572-585.
217. Gonzalez, V. M.; Fuertes, M. A.; Alonso, C.; Perez, J. M. Is cisplatin-induced cell death always produced by apoptosis? Mol. Pharmacol., 2001, 59, 657-663.
218. Orrenius, S.; Zhivotovsky, B.; Nicotera, P. Regulation of cell death: the calcium-apoptosis link. Nat. Rev. Mol. Cell Biol., 2003, 4, 552-565.
219. Garcia-Estrada, C.; Prada, C. F.; Fernandez-Rubio, C.; Rojo-Vazquez, F.; Balana-Fouce, R. DNA topoisomerases in apicomplexan parasites: promising targets for drug discovery. Proc. Biol. Sci., 2010, 277, 1777-1787.
220. Santisteban, M. S. (Structure of chromatin. I: Levels of DNA organization in the nucleus; nucleosome and chromatin fibres). Patho. Biol. Paris, 1994, 42, 868-883.
221. Sutcliffe, J. A.; Gootz, T. D.; Barrett, J. F. Biochemical characteristics and physiological significance of major DNA topoisomerases. Antimicrob. Agents Chemother., 1989, 33, 2027-2033.
222. Wang, J. C. DNA topoisomerases: why so many? J. Biol. Chem., 1991, 266, 6659-6662.
223. Champoux, J. J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem., 2001, 70, 369-413.
224. Ordonez, C.; Alfonso, J.; Balana-Fouce, R.; Ordonez, D. Functional expression of a DNA-topoisomerase IB from Cryptosporidium parvum. J. Biomed. Biotechnol., 2009, 2009, 837608.
225. Nelson, E. M.; Tewey, K. M.; Liu, L. F. Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci. U. S. A., 1984, 81, 1361-1365.
226. Facompre, M.; Goossens, J. F.; Bailly, C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1. Biochem. Pharmacol., 2001, 61, 299-310.
227. Cheesman, S. J. The topoisomerases of protozoan parasites. Parasitol. Today, 2000, 16, 277-281.
228. Lee, S.; Inselburg, J. In vitro sensitivity of Plasmodium falciparum to drugs that bind DNA or inhibit its synthesis. J. Parasitol., 1993, 79, 780-782.
229. Weber, J. L. Analysis of sequences from the extremely A + T-rich genome of Plasmodium falciparum. Gene, 1987, 52, 103-109.
230. Radding, C. M. Homologous pairing and strand exchange in genetic recombination. Annu. Rev. Genet., 1982, 16, 405-437.
231. Szostak, J. W.; Orr-Weaver, T. L.; Rothstein, R. J.; Stahl, F. W. The double-strand-break repair model for recombination. Cell, 1983, 33, 25-35.
232. Onishi, Y.; Azuma, Y.; Sato, Y.; Mizuno, Y.; Tadakuma, T.; Kizaki, H. Topoisomerase inhibitors induce apoptosis in thymocytes. Biochim. Biophys. Acta, 1993, 1175, 147-154.
233. Champoux, J. J. Domains of human topoisomerase I and associated functions. Prog. Nucleic Acid Res. Mol. Biol., 1998, 60, 111-132.
234. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 1991, 51, 1129-1136.
235. D'Arpa, P.; Beardmore, C.; Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 1990, 50, 6919-6924.
236. Bertrand, R.; O'Connor, P. M.; Kerrigan, D.; Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer, 1992, 28 A, 743-748.
237. Pommier, Y.; Leteurtre, F.; Fesen, M. R.; Fujimori, A.; Bertrand, R.; Solary, E.; Kohlhagen, G.; Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 1994, 12, 530-542.
238. Chatterjee, S.; Cheng, M. F.; Berger, N. A. Hypersensitivity to clinically useful alkylating agents and radiation in poly (ADP-ribose) polymerase-deficient cell lines. Cancer Commun., 1990, 2, 401-407.
239. Chatterjee, S.; Cheng, M. F.; Trivedi, D.; Petzold, S. J.; Berger, N. A. Camptothecin hypersensitivity in poly (adenosine diphosphateribose) polymerase-deficient cell lines. Cancer Commun., 1989, 1, 389-394.
240. Krishna, R.; Mayer, L. D. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur. J. Pharm. Sci., 2000, 11, 265-283.
241. Poddevin, B.; Riou, J. F.; Lavelle, F.; Pommier, Y. Dual topoisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. Mol. Pharmacol., 1993, 44, 767-774.
242. Denny, W. A. Dual topoisomerase I/II poisons as anticancer drugs. Expert Opin. Investig. Drugs, 1997, 6, 1845-1851.
243. Yamashita, Y.; Kawada, S.; Fujii, N.; Nakano, H. Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry, 1991, 30, 5838-5845.
244. Riou, J. F.; Fosse, P.; Nguyen, C. H.; Larsen, A. K.; Bissery, M. C.; Grondard, L.; Saucier, J. M.; Bisagni, E.; Lavelle, F. Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities. Cancer Res., 1993, 53, 5987-5993.
245. Utsugi, T.; Shibata, J.; Sugimoto, Y.; Aoyagi, K.; Wierzba, K.; Kobunai, T.; Terada, T.; Oh-hara, T.; Tsuruo, T.; Yamada, Y. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer. Cancer Res., 1996, 56, 2809-2814.
246. Gatto, B.; Zagotto, G.; Sissi, C.; Cera, C.; Uriarte, E.; Palu, G.; Capranico, G.; Palumbo, M. Peptidyl anthraquinones as potential antineoplastic drugs: synthesis, DNA binding, redox cycling, and biological activity. J. Med. Chem., 1996, 39, 3114-3122.
247. Gatto, B.; Sanders, M. M.; Yu, C.; Wu, H. Y.; Makhey, D.; La-Voie, E. J.; Liu, L. F. Identification of topoisomerase I as the cytotoxic target of the protoberberine alkaloid coralyne. Cancer Res, 1996, 56, 2795-2800.
248. Meikle, I.; Cummings, J.; Macpherson, J. S.; Hadfield, J. A.; Smyth, J. F. Biochemistry of topoisomerase I and II inhibition by anthracenyl-amino acid conjugates. Biochem. Pharmacol., 1995, 49, 1747-1757.
249. Meikle, I.; Cummings, J.; Macpherson, J. S.; Smyth, J. F. Identification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anticancer Drug Des, 1995, 10, 515-527.
250. Cummings, J.; Macpherson, J. S.; Meikle, I.; Smyth, J. F. Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance. Biochem. Pharmacol., 1996, 52, 979-990.
251. Davey, R. A.; Su, G. M.; Hargrave, R. M.; Harvie, R. M.; Baguley, B. C.; Davey, M. W. The potential of N-[2-(dimethylamino) ethyl]acridine-4-carboxamide to circumvent three multidrugresistance phenotypes in vitro. Cancer Chemother. Pharmacol., 1997, 39, 424-430.
252. Brana, M. F.; Castellano, J. M.; Perron, D.; Maher, C.; Conlon, D.; Bousquet, P. F.; George, J.; Qian, X. D.; Robinson, S. P. Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz (de, h) isoquinoline-1, 3-diones. J. Med. Chem., 1997, 40, 449-454.
253. Hao, X. Y.; Bergh, J.; Brodin, O.; Hellman, U.; Mannervik, B. Acquired resistance to cisplatin and doxorubicin in a small cell lung cancer cell line is correlated to elevated expression of glutathione-linked detoxification enzymes. Carcinogenesis, 1994, 15, 1167-1173.
254. Beck, W. T.; Danks, M. K. Mechanisms of resistance to drugs that inhibit DNA topoisomerases. Semin. Cancer Biol., 1991, 2, 235-244.
255. Kingma, P. S.; Burden, D. A.; Osheroff, N. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. Biochemistry, 1999, 38, 3457-3461. (Pubitemid 29149463)
256. Gilroy, K. L.; Leontiou, C.; Padget, K.; Lakey, J. H.; Austin, C. A. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced AT P hydrolysis activity. Nucleic Acids Res., 2006, 34, 1597-1607.
257. Patel, S.; Keller, B. A.; Fisher, L. M. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells. Mol. Pharmacol., 2000, 57, 784-791.
258. Chang, J. Y.; Liu, J. F.; Juang, S. H.; Liu, T. W.; Chen, L. T. Novel mutation of topoisomerase I in rendering cells resistant to camptothecin. Cancer Res., 2002, 62, 3716-3721.
259. Tanizawa, A.; Beitrand, R.; Kohlhagen, G.; Tabuchi, A.; Jenkins, J.; Pommier, Y. Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance. J. Biol. Chem., 1993, 268, 25463-25468.
260. Nitiss, J. L. Using yeast to study resistance to topoisomerase II-targeting drugs. Cancer Chemother. Pharmacol., 1994, 34 Suppl, S6-13.
261. Nitiss, J. L.; Vilalta, P. M.; Wu, H.; McMahon, J. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine. Mol. Pharmacol., 1994, 46, 773-777.
262. Tamura, H.; Kohchi, C.; Yamada, R.; Ikeda, T.; Koiwai, O.; Patterson, E.; Keene, J. D.; Okada, K.; Kjeldsen, E.; Nishikawa, K.; et al. Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. Nucleic Acids Res., 1991, 19, 69-75.
263. Nzila, A. The past, present and future of antifolates in the treatment of Plasmodium falciparum infection. J. Antimicrob. Chemother., 2006, 57, 1043-1054.
264. Nzila, A. M.; Mberu, E. K.; Sulo, J.; Dayo, H.; Winstanley, P. A.; Sibley, C. H.; Watkins, W. M. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. Antimicrob. Agents Chemother., 2000, 44, 991-996.
265. Korsinczky, M.; Chen, N.; Kotecka, B.; Saul, A.; Rieckmann, K.; Cheng, Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother., 2000, 44, 2100-2108.
266. Miyashita, T.; Krajewski, S.; Krajewska, M.; Wang, H. G.; Lin, H. K.; Liebermann, D. A.; Hoffman, B.; Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 1994, 9, 1799-1805.
267. Hendricks, C. B.; Rowinsky, E. K.; Grochow, L. B.; Donehower, R. C.; Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 1992, 52, 2268-2278.
268. Foote, S. J.; Thompson, J. K.; Cowman, A. F.; Kemp, D. J. Amplification of the multidrug resistance gene in some chloroquineresistant isolates of P. falciparum. Cell, 1989, 57, 921-930.
269. Wilson, C. M.; Serrano, A. E.; Wasley, A.; Bogenschutz, M. P.; Shankar, A. H.; Wirth, D. F. Amplification of a gene related to mammalian mdr genes in drug-resistant Plasmodium falciparum. Science, 1989, 244, 1184-1186.
270. Cowman, A. F. The P-glycoprotein homologues of Plasmodium falciparum: Are they involved in chloroquine resistance? Parasitol. Today, 1991, 7, 70-76.
271. Cowman, A. F.; Karcz, S.; Galatis, D.; Culvenor, J. G. A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J. Cell Biol, 1991, 113, 1033-1042.
272. Foote, S. J.; Kyle, D. E.; Martin, R. K.; Oduola, A. M.; Forsyth, K.; Kemp, D. J.; Cowman, A. F. Several alleles of the multidrugresistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature, 1990, 345, 255-258.
273. Kelly, J. X.; Smilkstein, M. J.; Brun, R.; Wittlin, S.; Cooper, R. A.; Lane, K. D.; Janowsky, A.; Johnson, R. A.; Dodean, R. A.; Winter, R.; Hinrichs, D. J.; Riscoe, M. K. Discovery of dual function acridones as a new antimalarial chemotype. Nature, 2009, 459, 270-273.
274. van Schalkwyk, D. A.; Egan, T. J. Quinoline-resistance reversing agents for the malaria parasite Plasmodium falciparum. Drug Resist. Updat., 2006, 9, 211-226.
275. Oduola, A. M.; Omitowoju, G. O.; Gerena, L.; Kyle, D. E.; Milhous, W. K.; Sowunmi, A.; Salako, L. A. Reversal of mefloquine resistance with penfluridol in isolates of Plasmodium falciparum from south-west Nigeria. Trans. R. Soc. Trop. Med. Hyg., 1993, 87, 81-83.
276. Peters, W.; Robinson, B. L. The chemotherapy of rodent malaria. XLVI. Reversal of mefloquine resistance in rodent Plasmodium. Ann. Trop. Med. Parasitol., 1991, 85, 5-10.
277. Bates, A. D.; Maxwell, A. Energy coupling in type II topoisomerases: why do they hydrolyze ATP? Biochemistry, 2007, 46, 7929-7941.
278. Riou, J. F.; Gabillot, M.; Philippe, M.; Schrevel, J.; Riou, G. Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage. Biochemistry, 1986, 25, 1471-1479.
279. Tosh, K.; Kilbey, B. The gene encoding topoisomerase I from the human malaria parasite Plasmodium falciparum. Gene, 1995, 163, 151-154.
280. Cheesman, S.; McAleese, S.; Goman, M.; Johnson, D.; Horrocks, P.; Ridley, R. G.; Kilbey, B. J. The gene encoding topoisomerase II from Plasmodium falciparum. Nucleic Acids Res., 1994, 22, 2547-2551.
281. Cheesman, S.; Horrocks, P.; Tosh, K.; Kilbey, B. Intraerythrocytic expression of topoisomerase II from Plasmodium falciparum is developmentally regulated. Mol. Biochem. Parasitol., 1998, 92, 39-46.
282. Tosh, K.; Cheesman, S.; Horrocks, P.; Kilbey, B. Plasmodium falciparum: stage-related expression of topoisomerase I. Exp. Parasitol., 1999, 91, 126-132.
283. Auparakkitanon, S.; Wilairat, P. Cleavage of DNA induced by 9-anilinoacridine inhibitors of topoisomerase II in the malaria parasite Plasmodium falciparum. Biochem. Biophys. Res. Commun., 2000, 269, 406-409.
284. Dahl, E. L.; Rosenthal, P. J. Apicoplast translation, transcription and genome replication: targets for antimalarial antibiotics. Trends Parasitol., 2008, 24, 279-284.
285. Fleige, T.; Soldati-Favre, D. Targeting the transcriptional and translational machinery of the endosymbiotic organelle in apicomplexans. Curr. Drug. Targets, 2008, 9, 948-956.
286. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem., 2005, 48, 6523-6543.
287. Benoit-Vical, F.; Lelievre, J.; Berry, A.; Deymier, C.; Dechy-Cabaret, O.; Cazelles, J.; Loup, C.; Robert, A.; Magnaval, J. F.; Meunier, B. Trioxaquines are new antimalarial agents active on all erythrocytic forms, including gametocytes. Antimicrob. Agents Chemother., 2007, 51, 1463-1472.
288. Cosledan, F.; Fraisse, L.; Pellet, A.; Guillou, F.; Mordmuller, B.; Kremsner, P. G.; Moreno, A.; Mazier, D.; Maffrand, J. P.; Meunier, B. Selection of a trioxaquine as an antimalarial drug candidate. Proc. Natl. Acad. Sci. U. S. A., 2008, 105, 17579-17584.
289. Loup, C.; Lelievre, J.; Benoit-Vical, F.; Meunier, B. Trioxaquines and heme-artemisinin adducts inhibit the in vitro formation of hemozoin better than chloroquine. Antimicrob. Agents Chemother., 2007, 51, 3768-3770.
290. Chavain, N.; Davioud-Charvet, E.; Trivelli, X.; Mbeki, L.; Rottmann, M.; Brun, R.; Biot, C. Antimalarial activities of ferroquine conjugates with either glutathione reductase inhibitors or glutathione depletors via a hydrolyzable amide linker. Bioorg. Med. Chem., 2009, 17, 8048-8059.
291. Muregi, F. W.; Ishih, A. Next-Generation Antimalarial Drugs: Hybrid Molecules as a New Strategy in Drug Design. Drug Develop. Res., 2010, 71, 20-32.
292. Nzila, A.; Ward, S. A.; Marsh, K.; Sims, P. F.; Hyde, J. E. Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy. Trends Parasitol., 2005, 21, 292-298. (Pubitemid 40726321)
293. Nzila, A.; Okombo, J.; Becker, R. P.; Chilengi, R.; Lang T.; Nichver, T. Anticancer agents against malaria: time to revisit? Trends Parasitol., 2010, 26, 125-129.
294. Rathod, P. K.; McErlean, T.; Lee, P. C. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 9389-9393.
295. Vangapandu, S.; Sachdeva, S.; Jain, M.; Singh, S.; Singh, P. P.; Kaul, C. L.; Jain, R. 8-quinolinamines and their pro prodrug conjugates as potent blood-schizontocidal antimalarial agents. Bioorg. Med. Chem., 2003, 11, 4557-4568.
296. Rajic, Z.; Kos, G.; Zorc, B.; Singh, P. P.; Singh, S. Macromolecular prodrugs. XII. Primaquine conjugates: synthesis and preliminary antimalarial evaluation. Acta Pharm., 2009, 59, 107-115.
297. Basco, L. K.; Dechy-Cabaret, O.; Ndounga, M.; Meche, F. S.; Robert, A.; Meunier, B. In vitro activities of DU-1102, a new trioxaquine derivative, against Plasmodium falciparum isolates. Antimicrob. Agents Chemother., 2001, 45, 1886-1888.
298. Delhaes, L.; Abessolo, H.; Biot, C.; Berry, L.; Delcourt, P.; Maciejewski, L.; Brocard, J.; Camus, D.; Dive, D. In vitro and in vivo antimalarial activity of ferrochloroquine, a ferrocenyl analogue of chloroquine against chloroquine-resistant malaria parasites. Parasitol. Res., 2001, 87, 239-244.
299. Atteke, C.; Ndong, J. M.; Aubouy, A.; Maciejewski, L.; Brocard, J.; Lebibi, J.; Deloron, P. In vitro susceptibility to a new antimalarial organometallic analogue, ferroquine, of Plasmodium falciparum isolates from the Haut-Ogooue region of Gabon. J. Antimicrob. Chemother., 2003, 51, 1021-1024.
300. Clinical Trials.gov 2010]. Dose ranging study of ferroquine with artesunate in African adults and children with uncomplicated Plasmodium falciparum malaria[FARM]. http://clinicaltrials.gov/ct2/show/NCT00988507 (Accessed June, 2010).
301. Bellot, F.; Cosledan, F.; Vendier, L.; Brocard, J.; Meunier, B.; Robert, A. Trioxaferroquines as new hybrid antimalarial drugs. J. Med. Chem., 2010, 53, 4103-4109.
302. Leblanc, C.; Boyen, C.; Richard, O.; Bonnard, G.; Grienenberger, J. M.; Kloareg, B. Complete sequence of the mitochondrial DNA of the rhodophyte Chondrus crispus[Gigartinales]. Gene content and genome organization. J. Mol. Biol., 1995, 250, 484-495.
303. Sijwali, P. S.; Kato, K.; Seydel, K. B.; Gut, J.; Lehman, J.; Klemba, M.; Goldberg, D. E.; Miller, L. H.; Rosenthal, P. J. Plasmodium falciparum cysteine protease falcipain-1 is not essential in erythrocytic stage malaria parasites. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 8721-8726.
304. Sijwali, P. S.; Rosenthal, P. J. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum. Proc. Natl. Acad. Sci. U. S. A., 2004, 101, 4384-4389.
305. Sijwali, P. S.; Koo, J.; Singh, N.; Rosenthal, P. J. Gene disruptions demonstrate independent roles for the four falcipain cysteine proteases of Plasmodium falciparum. Mol. Biochem. Parasitol., 2006, 150, 96-106.
306. Sajid, M.; McKerrow, J. H. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol., 2002, 120, 1-21.
307. Singh, A.; Rosenthal, P. J. Comparison of efficacies of cysteine protease inhibitors against five strains of Plasmodium falciparum. Antimicrob. Agents Chemother., 2001, 45, 949-951.
308. Rosenthal, P. J.; Lee, G. K.; Smith, R. E. Inhibition of a Plasmodium vinckei cysteine proteinase cures murine malaria. J. Clin. Invest., 1993, 91, 1052-1056.
309. Rosenthal, P. J.; McKerrow, J. H.; Aikawa, M.; Nagasawa, H.; Leech, J. H. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum. J. Clin. Invest., 1988, 82, 1560-1566.
310. Rosenthal, P. J.; Olson, J. E.; Lee, G. K.; Palmer, J. T.; Klaus, J. L.; Rasnick, D. Antimalarial effects of vinyl sulfone cysteine proteinase inhibitors. Antimicrob. Agents Chemother., 1996, 40, 1600-1603.
311. Rosenthal, P. J.; Wollish, W. S.; Palmer, J. T.; Rasnick, D. Antimalarial effects of peptide inhibitors of a Plasmodium falciparum cysteine proteinase. J. Clin. Invest., 1991, 88, 1467-1472.
312. Li, R.; Kenyon, G. L.; Cohen, F. E.; Chen, X.; Gong, B.; Dominguez, J. N.; Davidson, E.; Kurzban, G.; Miller, R. E.; Nuzum, E. O.; et al. In vitro antimalarial activity of chalcones and their derivatives. J. Med. Chem., 1995, 38, 5031-5037.
313. Dominguez, J. N.; Lopez, S.; Charris, J.; Iarruso, L.; Lobo, G.; Semenov, A.; Olson, J. E.; Rosenthal, P. J. Synthesis and antimalarial effects of phenothiazine inhibitors of a Plasmodium falciparum cysteine protease. J. Med. Chem., 1997, 40, 2726-2732.
314. Shenai, B. R.; Semenov, A. V.; Rosenthal, P. J. Stage-specific antimalarial activity of cysteine protease inhibitors. Biol. Chem., 2002, 383, 843-847.
315. Wickham, M. E.; Culvenor, J. G.; Cowman, A. F. Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte. J. Biol. Chem., 2003, 278, 37658-37663.
316. Salmon, B. L.; Oksman, A.; Goldberg, D. E. Malaria parasite exit from the host erythrocyte: a two-step process requiring extraerythrocytic proteolysis. Proc. Natl. Acad. Sci. U. S. A., 2001, 98, 271-276.
317. Capela, R.; Oliveira, R.; Goncalves, L. M.; Domingos, A.; Gut, J.; Rosenthal, P. J.; Lopes, F.; Moreira, R. Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg. Med. Chem. Lett., 2009, 19, 3229-3232.
318. Chiyanzu, I.; Clarkson, C.; Smith, P. J.; Lehman, J.; Gut, J.; Rosenthal, P. J.; Chibale, K. Design, synthesis and anti-plasmodial evaluation in vitro of new 4-aminoquinoline isatin derivatives. Bioorg. Med. Chem., 2005, 13, 3249-3261.
319. Atamna, H.; Ginsburg, H. The malaria parasite supplies glutathione to its host cell-investigation of glutathione transport and metabolism in human erythrocytes infected with Plasmodium falciparum. Eur. J. Biochem., 1997, 250, 670-679.
320. Morin, C.; Besset, T.; Moutet, J. C.; Fayolle, M.; Bruckner, M.; Limosin, D.; Becker, K.; Davioud-Charvet, E. The aza-analogues of 1, 4-naphthoquinones are potent substrates and inhibitors of plasmodial thioredoxin and glutathione reductases and of human erythrocyte glutathione reductase. Org. Biomol. Chem., 2008, 6, 2731-2742.
321. Biot, C.; Dessolin, J.; Grellier, P.; Davioud-Charvet, E. Doubledrug development against antioxidant enzymes from Plasmodium falciparum. Redox Rep., 2003, 8, 280-283.
322. Deponte, M.; Becker, K. Glutathione S-transferase from malarial parasites: structural and functional aspects. Methods Enzymol., 2005, 401, 241-253.
323. Friebolin, W.; Jannack, B.; Wenzel, N.; Furrer, J.; Oeser, T.; Sanchez, C. P.; Lanzer, M.; Yardley, V.; Becker, K.; Davioud-Charvet, E. Antimalarial dual drugs based on potent inhibitors of glutathione reductase from Plasmodium falciparum. J. Med. Chem., 2008, 51, 1260-1277.
324. Basco, L. K.; Mitaku, S.; Skaltsounis, A. L.; Ravelomanantsoa, N.; Tillequin, F.; Koch, M.; Le Bras, J. In vitro activities of furoquinoline and acridone alkaloids against Plasmodium falciparum. Antimicrob. Agents Chemother., 1994, 38, 1169-1171. (Pubitemid 24150859)
325. Winter, R. W.; Kelly, J. X.; Smilkstein, M. J.; Dodean, R.; Bagby, G. C.; Rathbun, R. K.; Levin, J. I.; Hinrichs, D.; Riscoe, M. K. Evaluation and lead optimization of anti-malarial acridones. Exp. Parasitol., 2006, 114, 47-56.
326. Dorn, A.; Scovill, J. P.; Ellis, W. Y.; Matile, H.; Ridley, R. G.; Vennerstrom, J. L. Short report: floxacrine analog WR 243251 inhibits hematin polymerization. Am. J. Trop. Med. Hyg., 2001, 65, 19-20.
327. Chou, A. C.; Fitch, C. D. Control of heme polymerase by chloroquine and other quinoline derivatives. Biochem. Biophys. Res. Commun., 1993, 195, 422-427.
328. Dorn, A.; Vippagunta, S. R.; Matile, H.; Jaquet, C.; Vennerstrom, J. L.; Ridley, R. G. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem. Pharmacol., 1998, 55, 727-736.
329. Auparakkitanon, S.; Noonpakdee, W.; Ralph, R. K.; Denny, W. A.; Wilairat, P. Antimalarial 9-anilinoacridine compounds directed at hematin. Antimicrob. Agents Chemother., 2003, 47, 3708-3712.
330. Auparakkitanon, S.; Chapoomram, S.; Kuaha, K.; Chirachariyavej, T.; Wilairat, P. Targeting of hematin by the antimalarial pyronaridine. Antimicrob. Agents Chemother., 2006, 50, 2197-2200.
331. Gamage, S. A.; Tepsiri, N.; Wilairat, P.; Wojcik, S. J.; Figgitt, D. P.; Ralph, R. K.; Denny, W. A. Synthesis and in vitro evaluation of 9-anilino-3, 6-diaminoacridines active against a multidrug-resistant strain of the malaria parasite Plasmodium falciparum. J. Med. Chem., 1994, 37, 1486-1494.
332. Suswam, E.; Kyle, D.; Lang-Unnasch, N. Plasmodium falciparum: the effects of atovaquone resistance on respiration. Exp. Parasitol., 2001, 98, 180-187.
333. Vaidya, A. B.; Mather, M. W. A post-genomic view of the mitochondrion in malaria parasites. Curr. Top. Microbiol. Immunol., 2005, 295, 233-250.
334. Mather, M. W.; Darrouzet, E.; Valkova-Valchanova, M.; Cooley, J. W.; McIntosh, M. T.; Daldal, F.; Vaidya, A. B. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J. Biol. Chem, 2005, 280, 27458-27465.
335. Figgitt, D.; Denny, W.; Chavalitshewinkoon, P.; Wilairat, P.; Ralph, R. In vitro study of anticancer acridines as potential antitrypanosomal and antimalarial agents. Antimicrob. Agents Chemother., 1992, 36, 1644-1647.
336. Chavalitshewinkoon, P.; Wilairat, P.; Gamage, S.; Denny, W.; Figgitt, D.; Ralph, R. Structure-activity relationships and modes of action of 9-anilinoacridines against chloroquine-resistant Plasmodium falciparum in vitro. Antimicrob. Agents Chemother., 1993, 37, 403-406.
337. Tshefu, A. K.; Gaye, O.; Kayentao, K.; Thompson, R.; Bhatt, K. M.; Sesay, S. S.; Bustos, D. G.; Tjitra, E.; Bedu-Addo, G.; Borghini-Fuhrer, I.; Duparc, S.; Shin, C. S.; Fleckenstein, L. Efficacy and safety of a fixed-dose oral combination of pyronaridineartesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet, 2010, 375, 1457-1467.
338. Olliaro, P.; Wells, T. N. The global portfolio of new antimalarial medicines under development. Clin. Pharmacol. Ther., 2009, 85, 584-595.
339. Pukrittayakamee, S.; Chotivanich, K.; Chantra, A.; Clemens, R.; Looareesuwan, S.; White, N. J. Activities of artesunate and primaquine against asexual-and sexual-stage parasites in falciparum malaria. Antimicrob. Agents Chemother., 2004, 48, 1329-1334.
340. Chavalitshewinkoon-Petmitr, P.; Pongvilairat, G.; Ralph, R. K.; Denny, W. A.; Wilairat, P. Inhibitory effects of 9-anilinoacridines on Plasmodium falciparum gametocytes. Trop. Med. Int. Health, 2001, 6, 42-45.
341. Vennerstrom, J. L.; Arbe-Barnes, S.; Brun, R.; Charman, S. A.; Chiu, F. C.; Chollet, J.; Dong, Y.; Dorn, A.; Hunziker, D.; Matile, H.; McIntosh, K.; Padmanilayam, M.; Santo Tomas, J.; Scheurer, C.; Scorneaux, B.; Tang, Y.; Urwyler, H.; Wittlin, S.; Charman, W. N. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature, 2004, 430, 900-904.
342. Hartwig, C. L.; Rosenthal, A. S.; D'Angelo, J.; Griffin, C. E.; Posner, G. H.; Cooper, R. A. Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem. Pharmacol., 2009, 77, 322-336.
343. Eckstein-Ludwig, U.; Webb, R. J.; Van Goethem, I. D.; East, J. M.; Lee, A. G.; Kimura, M.; O'Neill, P. M.; Bray, P. G.; Ward, S. A.; Krishna, S. Artemisinins target the SERCA of Plasmodium falciparum. Nature, 2003, 424, 957-961.
344. Scott, M. D.; Meshnick, S. R.; Williams, R. A.; Chiu, D. T.; Pan, H. C.; Lubin, B. H.; Kuypers, F. A. Qinghaosu-mediated oxidation in normal and abnormal erythrocytes. J. Lab. Clin. Med., 1989, 114, 401-406.
345. Bray, P. G.; Martin, R. E.; Tilley, L.; Ward, S. A.; Kirk, K.; Fidock, D. A. Defining the role of PfCRT in Plasmodium falciparum chloroquine resistance. Mol. Microbiol., 2005, 56, 323-333.
346. Isola, E. L.; Lammel, E. M.; Gonzalez Cappa, S. M. Trypanosoma cruzi: differentiation to metacyclic trypomastigotes in the presence of ADP-ribosyltransferase inhibitors. Exp. Parasitol., 1987, 64, 424-429.
347. Villamil, S. F.; Podesta, D.; Molina Portela, M. D.; Stoppani, A. Characterization of poly[ADP-ribose]polymerase from Crithidia fasciculata: enzyme inhibition by beta-lapachone. Mol. Biochem. Parasitol., 2001, 115, 249-256.
348. Weltin, D.; Marchal, J.; Dufour, P.; Potworowski, E.; Oth, D.; Bischoff, P. Effect of 6[5H]-phenanthridinone, an inhibitor of poly (ADP-ribose) polymerase, on cultured tumor cells. Oncol. Res., 1994, 6, 399-403.
349. Mendeleyev, J.; Kirsten, E.; Hakam, A.; Buki, K. G.; Kun, E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide. Metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem. Pharmacol., 1995, 50, 705-714.
350. Bowman, K. J.; White, A.; Golding, B. T.; Griffin, R. J.; Curtin, N. J. Potentiation of anti-cancer agent cytotoxicity by the potent poly (ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer, 1998, 78, 1269-1277.
351. Tentori, L.; Leonetti, C.; Scarsella, M.; d'Amati, G.; Portarena, I.; Zupi, G.; Bonmassar, E.; Graziani, G. Combined treatment with temozolomide and poly (ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood, 2002, 99, 2241-2244.
352. Wenzel, N. I.; Chavain, N.; Wang, Y.; Friebolin, W.; Maes, L.; Pradines, B.; Lanzer, M.; Yardley, V.; Brun, R.; Herold-Mende, C.; Biot, C.; Toth, K.; Davioud-Charvet, E. Antimalarial versus cytotoxic properties of dual drugs derived from 4-aminoquinolines and Mannich bases: interaction with DNA. J. Med. Chem., 2010, 53, 3214-3226.
353. Shiobara, M.; Miyazaki, M.; Ito, H.; Togawa, A.; Nakajima, N.; Nomura, F.; Morinaga, N.; Noda, M. Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J. Gastroenterol. Hepatol., 2001, 16, 338-344.
354. Pommier, Y.; Redon, C.; Rao, V. A.; Seiler, J. A.; Sordet, O.; Takemura, H.; Antony, S.; Meng, L.; Liao, Z.; Kohlhagen, G.; Zhang, H.; Kohn, K. W. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat. Res., 2003, 532, 173-203.
355. Reguera, R. M.; Redondo, C. M.; Gutierrez de Prado, R.; Perez-Pertejo, Y.; Balana-Fouce, R. DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim. Biophys. Acta, 2006, 1759, 117-131.
356. Balana-Fouce, R.; Redondo, C. M.; Perez-Pertejo, Y.; Diaz-Gonzalez, R.; Reguera, R. M. Targeting atypical trypanosomatid DNA topoisomerase I. Drug. Discov. Today, 2006, 11, 733-740.
357. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer, 2006, 6, 789-802.
358. Bodley, A. L.; Cumming, J. N.; Shapiro, T. A. Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum. Biochem. Pharmacol., 1998, 55, 709-711.
359. Chen, A. Y.; Liu, L. F. Mechanisms of resistance to topoisomerase inhibitors. Cancer Treat. Res., 1994, 73, 263-281.
360. Kelly, J. M.; McRobert, L.; Baker, D. A. Evidence on the chromosomal location of centromeric DNA in Plasmodium falciparum from etoposide-mediated topoisomerase-II cleavage. Proc. Natl. Acad. Sci. U. S. A., 2006, 103, 6706-6711.
361. Zwelling, L. A.; Mitchell, M. J.; Satitpunwaycha, P.; Mayes, J.; Altschuler, E.; Hinds, M.; Baguley, B. C. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or-resistant forms of topoisomerase II: use of computer simulations in new drug development. Cancer Res., 1992, 52, 209-217.
362. Chavalitshewinkoon-Petmitr, P.; Pongvilairat, G.; Auparakkitanon, S.; Wilairat, P. Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro. Parasitol. Int., 2000, 48, 275-280.
363. Fu, S.; Xiao, S. H. Pyronaridine: A new antimalarial drug. Parasitol. Today, 1991, 7, 310-313.
364. Werbovetz, K. A.; Spoors, P. G.; Pearson, R. D.; Macdonald, T. L. Cleavable complex formation in Leishmania chagasi treated with anilinoacridines. Mol. Biochem. Parasitol., 1994, 65, 1-10.
365. Mesa-Valle, C. M.; Castilla-Calvente, J.; Sanchez-Moreno, M.; Moraleda-Lindez, V.; Barbe, J.; Osuna, A. Activity and mode of action of acridine compounds against Leishmania donovani. Antimicrob. Agents Chemother., 1996, 40, 684-690.
366. Auparakkitanon, S.; Poonchareon, K.; Sopitthummakhun, K.; Wilairat, P. Interactions between antiplasmodial 3, 6-diamino-1'-dimethyl-9-anilinoacridine and hematin and concanamycin A. Southeast Asian J. Trop. Med. Public Health, 2007, 38, 979-982.
367. Lisgarten, J. N.; Coll, M.; Portugal, J.; Wright, C. W.; Aymami, J. The antimalarial and cytotoxic drug cryptolepine intercalates into DNA at cytosine-cytosine sites. Nat. Struct. Biol., 2002, 9, 57-60.
368. Arzel, E.; Rocca, P.; Grellier, P.; Labaeid, M.; Frappier, F.; Gueritte, F.; Gaspard, C.; Marsais, F.; Godard, A.; Queguiner, G. New synthesis of benzo-delta-carbolines, cryptolepines, and their salts: in vitro cytotoxic, antiplasmodial, and antitrypanosomal activities of delta-carbolines, benzo-delta-carbolines, and cryptolepines. J. Med. Chem., 2001, 44, 949-960.
369. Bonjean, K.; De Pauw-Gillet, M. C.; Defresne, M. P.; Colson, P.; Houssier, C.; Dassonneville, L.; Bailly, C.; Greimers, R.; Wright, C.; Quetin-Leclercq, J.; Tits, M.; Angenot, L. The DNA intercalating alkaloid cryptolepine interferes with topoisomerase II and inhibits primarily DNA synthesis in B16 melanoma cells. Biochemistry, 1998, 37, 5136-5146.
370. Wright, C. W.; Addae-Kyereme, J.; Breen, A. G.; Brown, J. E.; Cox, M. F.; Croft, S. L.; Gokcek, Y.; Kendrick, H.; Phillips, R. M.; Pollet, P. L. Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. J. Med. Chem., 2001, 44, 3187-3194.
371. Ramharter, M.; Kurth, F.; Schreier, A. C.; Nemeth, J.; Glasenapp, I.; Belard, S.; Schlie, M.; Kammer, J.; Koumba, P. K.; Cisse, B.; Mordmuller, B.; Lell, B.; Issifou, S.; Oeuvray, C.; Fleckenstein, L.; Kremsner, P. G. Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon. J. Infect. Dis., 2008, 198, 911-919.
372. Hooper, D. C.; Wolfson, J. S. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother., 1985, 28, 716-721.
373. Drlica, K. Mechanism of fluoroquinolone action. Curr. Opin. Microbiol., 1999, 2, 504-508.
374. Wolfson, J. S.; Hooper, D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob. Agents Chemother., 1985, 28, 581-586.
375. Hunt, S. Y.; Detering, C.; Varani, G.; Jacobus, D. P.; Schiehser, G. A.; Shieh, H. M.; Nevchas, I.; Terpinski, J.; Sibley, C. H. Identification of the optimal third generation antifolate against P. falciparum and P. vivax. Mol. Biochem. Parasitol., 2005, 144, 198-205.
376. Shearer, T. W.; Kozar, M. P.; O'Neil, M. T.; Smith, P. L.; Schiehser, G. A.; Jacobus, D. P.; Diaz, D. S.; Yang, Y. S.; Milhous, W. K.; Skillman, D. R. In vitro metabolism of phenoxypropoxybiguanide analogues in human liver microsomes to potent antimalarial dihydrotriazines. J. Med. Chem., 2005, 48, 2805-2813.
377. Xie, L. H.; Li, Q.; Lin, A. J.; Smith, K.; Zhang, J.; Skillman, D. S. New potential antimalarial agents: therapeutic-index evaluation of pyrroloquinazolinediamine and its prodrugs in a rat model of severe malaria. Antimicrob. Agents Chemother., 2006, 50, 1649-1655.
378. Muregi, F. W.; Kino, H.; Ishih, A. Plasmodium berghei: lack of antimalarial activity of an analogue of folate precursor, 2, 4-diamino-6-hydroxymethylpteridine in a mouse model. Exp. Parasitol., 2008, 120, 286-289.
379. Walter, R. D.; Bergmann, B.; Kansy, M.; Wiese, M.; Seydel, J. K. Pyrimethamin-resistant Plasmodium falciparum lack crossresistance to methotrexate and 2,4-diamino-5-[substituted benzyl]pyrimidines. Parasitol. Res., 1991, 77, 346-350.
380. Golenser, J.; Casuto, D.; Pollack, Y. Plasmodium falciparum: in vitro induction of resistance to aminopterin. Exp. Parasitol., 1981, 52, 371-377.
381. Nduati, E.; Diriye, A.; Ommeh, S.; Mwai, L.; Kiara, S.; Masseno, V.; Kokwaro, G.; Nzila, A. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol. Res., 2008, 102, 1227-1234.
382. Nduati, E.; Hunt, S.; Kamau, E. M.; Nzila, A. 2, 4-diaminopteridine-based compounds as precursors for de novo synthesis of antifolates: a novel class of antimalarials. Antimicrob. Agents Chemother., 2005, 49, 3652-3657.
383. Irungu, B.; Kiboi, D.; Langat, B.; Rukunga, G.; Wittlin, S.; Nzila, A. Methotrexate and aminopterin lack in vivo antimalarial activity against murine malaria species. Exp. Parasitol., 2009, 123, 118-121.